Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009)

NCT01304498 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

600

Enrollment

INDUSTRY

Sponsor class

Conditions

Human Papillomavirus

Interventions

BIOLOGICAL: V503
BIOLOGICAL: GARDASIL

Sponsor

Merck Sharp & Dohme LLC